NCT00982878View on ClinicalTrials.gov

The Maraviroc Central Nervous System (CNS) Study

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

February 28, 2011

Conditions
HIV Infections
Interventions
DRUG

Maraviroc

150mg twice daily

Trial Locations (1)

W2 1NY

Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Imperial College London

OTHER

NCT00982878 - The Maraviroc Central Nervous System (CNS) Study | Biotech Hunter | Biotech Hunter